title: Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins.
abstract: For a panel of cancer related proteins, the aim was to shed light on which molecular level the expression of each protein was mainly regulated in breast tumors, and to investigate whether differences in regulation were reflected in different molecular subtypes. DNA, mRNA and protein lysates from 251 breast tumor specimens were analyzed using appropriate microarray technologies. Data from all three levels were available for 52 proteins selected for their known involvement in cancer, primarily through the PI3K/Akt pathway. For every protein, in cis Spearman rank correlations between the three molecular levels were calculated across all samples and within each intrinsic gene expression subtype, enabling 63 comparisons altogether due to multiple gene probes matching to single proteins. Subtype-specific relationships between the three molecular levels were studied by calculating the variance of subtype-specific correlation and differences between overall and average subtype-specific correlation. The findings were validated in an external dataset comprising 703 breast tumor specimens. The proteins were sorted into four groups based on the calculated rank correlation values between the three molecular levels. Group A consisted of eight proteins with significant correlation between DNA copy number levels and mRNA expression, and between mRNA expression and protein expression (Bonferroni adjusted p < 0.05). Group B consisted of 14 proteins with significant correlation between mRNA expression and protein expression. Group C consisted of 15 proteins with significant correlation between copy number levels and mRNA expression. For the remaining 25 proteins (group D), no significant correlations was observed. Stratification of tumors according to intrinsic subtype enabled identification of positive correlations between copy number levels, mRNA and protein expression that were undetectable when considering the entire sample set. Protein pairings that either demonstrated high variance in correlation values between subtypes, or between subtypes and the total dataset were studied in particular. The protein expression of cleaved caspase 7 was most highly expressed, and correlated highest to CASP7 gene expression within the basal-like subtype, accompanied by the lowest amounts of hsa-miR-29c. Luminal A-like subtype demonstrated highest amounts of hsa-miR-29c (a miRNA with a putative target sequence in CASP7 mRNA), low expression of cleaved caspase 7 and low correlation to CASP7 gene expression. Such pattern might be an indication of hsa-miR-29c miRNA functioning as a repressor of translation of CASP7 within the luminal-A subtype. Across the entire cohort no correlation was found between CCNB1 copy number and gene expression. However, within most gene intrinsic subtypes, mRNA and protein expression of cyclin B1 was found positively correlated to copy number data, suggesting that copy number can affect the overall expression of this protein. Aberrations of cyclin B1 copy number also identified patients with reduced overall survival within each subtype. Based on correlation between the three molecular levels, genes and their products could be sorted into four groups for which the expression was likely to be regulated at different molecular levels. Further stratification suggested subtype-specific regulation that was not evident across the entire sample set.
authors.affiliation: Department of Genetics, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, N-0310 Oslo, Norway. simen@amh.no
authors.forename: Simen
authors.initials: S
authors.lastname: Myhre
authors.forename: Ole-Christian
authors.initials: OC
authors.lastname: Lingjærde
authors.forename: Bryan T
authors.initials: BT
authors.lastname: Hennessy
authors.forename: Miriam R
authors.initials: MR
authors.lastname: Aure
authors.forename: Mark S
authors.initials: MS
authors.lastname: Carey
authors.forename: Jan
authors.initials: J
authors.lastname: Alsner
authors.forename: Trine
authors.initials: T
authors.lastname: Tramm
authors.forename: Jens
authors.initials: J
authors.lastname: Overgaard
authors.forename: Gordon B
authors.initials: GB
authors.lastname: Mills
authors.forename: Anne-Lise
authors.initials: AL
authors.lastname: Børresen-Dale
authors.forename: Therese
authors.initials: T
authors.lastname: Sørlie
mesh_terms: D001940:Breast / Q000378:metabolism; D001943:Breast Neoplasms / Q000175:diagnosis / Q000235:genetics*; D053179:Caspase 7 / Q000235:genetics; D056744:Cyclin B1 / Q000235:genetics; D005260:Female; D018628:Gene Dosage; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D035683:MicroRNAs / Q000235:genetics; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics*; D016019:Survival Analysis
chemical_list: D056744:Cyclin B1; C532045:MIRN29a microRNA, human; D035683:MicroRNAs; D012333:RNA, Messenger; C505520:CASP7 protein, human; D053179:Caspase 7
references.citation: Oncogene. 1996 Jul 4;13(1):63-72
references.pmid: 8700555
references.citation: Br J Cancer. 2009 Apr 7;100(7):1055-60
references.pmid: 19293801
references.citation: Clin Cancer Res. 1996 Jun;2(6):923-8
references.pmid: 9816251
references.citation: Clin Cancer Res. 2007 Jan 1;13(1):81-9
references.pmid: 17200342
references.citation: Nature. 2010 Aug 12;466(7308):835-40
references.pmid: 20703300
references.citation: Mol Oncol. 2007 Sep;1(2):160-71
references.pmid: 19383292
references.citation: Lancet. 1998 May 16;351(9114):1451-67
references.pmid: 9605801
references.citation: N Engl J Med. 1989 Feb 23;320(8):479-84
references.pmid: 2644532
references.citation: Genes Dev. 2009 Jul 1;23(13):1494-504
references.pmid: 19571179
references.citation: Int J Epidemiol. 2010 Oct;39(5):1137-50
references.pmid: 21051364
references.citation: J Cell Sci. 2001 Oct;114(Pt 20):3771-8
references.pmid: 11707529
references.citation: Cancer Res. 2002 Nov 1;62(21):6240-5
references.pmid: 12414653
references.citation: J Clin Oncol. 2003 Sep 15;21(18):3469-78
references.pmid: 12972522
references.citation: Am J Med Genet A. 2009 May;149A(5):894-905
references.pmid: 19363806
references.citation: Brief Funct Genomic Proteomic. 2002 Oct;1(3):305-15
references.pmid: 15239896
references.citation: Sci Transl Med. 2010 Jun 30;2(38):38ra47
references.pmid: 20592421
references.citation: Breast Cancer Res. 2010;12(4):R65
references.pmid: 20799965
references.citation: Cancer. 1980 Jan 15;45(2):349-53
references.pmid: 7351016
references.citation: Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23
references.pmid: 12829800
references.citation: Proteomics. 2009 Oct;9(20):4632-41
references.pmid: 19743430
references.citation: Int J Cancer. 1997 Apr 22;74(2):171-4
references.pmid: 9133450
references.citation: Mol Cell Biol. 1995 Apr;15(4):2191-6
references.pmid: 7891714
references.citation: Int J Cancer. 2010 Aug 15;127(4):961-7
references.pmid: 19957331
references.citation: Mol Oncol. 2010 Aug;4(4):357-68
references.pmid: 20663721
references.citation: Cancer Metastasis Rev. 2010 Dec;29(4):751-9
references.pmid: 20922461
references.citation: Int J Cancer. 2010 Jul 15;127(2):355-60
references.pmid: 19904758
references.citation: BMC Cancer. 2008 Dec 29;8:391
references.pmid: 19113992
references.citation: Mol Syst Biol. 2012;8:608
references.pmid: 22968442
references.citation: Science. 2007 Feb 9;315(5813):848-53
references.pmid: 17289997
references.citation: Mol Oncol. 2013 Jun;7(3):704-18
references.pmid: 23562353
references.citation: Radiother Oncol. 2009 Jan;90(1):74-9
references.pmid: 18471914
references.citation: BMC Genomics. 2009 Aug 07;10:365
references.pmid: 19660143
references.citation: PLoS One. 2010 Nov 19;5(11):e14002
references.pmid: 21124964
references.citation: Cell. 2009 Jan 23;136(2):215-33
references.pmid: 19167326
references.citation: Nat Med. 2004 Nov;10(11):1251-6
references.pmid: 15502842
references.citation: Proteomics. 2003 Nov;3(11):2091-100
references.pmid: 14595807
references.citation: Clin Cancer Res. 2009 Jun 1;15(11):3654-62
references.pmid: 19470724
references.citation: PLoS One. 2011 Feb 22;6(2):e16915
references.pmid: 21364938
references.citation: Nat Genet. 2003 Mar;33 Suppl:245-54
references.pmid: 12610534
references.citation: Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12963-8
references.pmid: 12297621
references.citation: Clin Proteomics. 2010 Dec;6(4):129-51
references.pmid: 21691416
references.citation: Cancer Res. 2010 Mar 1;70(5):1916-24
references.pmid: 20160038
references.citation: Breast Cancer Res. 2007;9(3):R30
references.pmid: 17504517
references.citation: Oncogene. 1987;1(4):423-30
references.pmid: 3330785
references.citation: Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
references.pmid: 11553815
references.citation: N Engl J Med. 2006 Dec 28;355(26):2733-43
references.pmid: 17192538
references.citation: Cancer Res. 2009 Aug 1;69(15):6299-306
references.pmid: 19602588
references.citation: BMC Genomics. 2008 Aug 08;9:379
references.pmid: 18691401
references.citation: Mod Pathol. 2006 Jul;19(7):999-1009
references.pmid: 16648863
references.citation: J Clin Oncol. 2006 May 20;24(15):2268-75
references.pmid: 16618947
references.citation: Mol Cancer Ther. 2006 Oct;5(10):2512-21
references.pmid: 17041095
references.citation: Anticancer Res. 1999 Jan-Feb;19(1A):163-9
references.pmid: 10226538
references.citation: Nature. 2008 Sep 4;455(7209):64-71
references.pmid: 18668037
references.citation: Oncology (Williston Park). 2010 Apr 30;24(5):410-5
references.pmid: 20480738
references.citation: Nat Biotechnol. 2006 Sep;24(9):1151-61
references.pmid: 16964229
references.citation: Nat Genet. 2008 Jul;40(7):807-8; author reply 810-2
references.pmid: 18583965
references.citation: J Biol Chem. 2009 Sep 11;284(37):25441-9
references.pmid: 19617626
references.citation: Nat Biotechnol. 2007 Jan;25(1):117-24
references.pmid: 17187058